Table 5.

Risk of epithelial ovarian cancer associated with exclusive use of ET and EPT hormone therapy by BMI

ET*
EPT*
BMI <25
BMI ≥ 25
BMI <25
BMI ≥ 25
Controls, nCases, nOR (95% CI)Controls, nCases, nOR (95% CI)Controls, nCases, nOR (95% CI)Controls, nCases, nOR (95% CI)
Never used3211911.02892461.03211911.02892461.0
Ever67591.9 (1.2-2.9)100621.0 (0.6-1.4)168810.9 (0.7-1.4)153720.6 (0.4-0.9)
Duration of use
    <60 mo24151.3 (0.6-2.6)43230.8 (0.4-1.4)59280.9 (0.5-1.5)71230.4 (0.2-0.7)
    60-119 mo1391.4 (0.6-3.5)13121.3 (0.5-2.9)48281.2 (0.7-2.1)35210.8 (0.4-1.4)
    120+ mo30352.7 (1.5-4.8)44271.1 (0.6-1.9)61250.9 (0.5-1.5)47281.0 (0.6-1.7)
Recency of use
    Current37362.0 (1.2-3.5)47280.9 (0.5-1.6)68411.1 (0.7-1.8)54421.0 (0.6-1.6)
    Former30231.7 (0.9-3.1)53341.0 (0.6-1.6)100400.8 (0.5-1.2)99300.4 (0.3-0.7)
  • * P interaction for HT use with BMI (assessed 5 y before reference date) = 0.02, 0.09, and 0.05 for ever, duration, and recency of ET use; and 0.09, 0.14, and 0.11 for ever, duration, and recency of EPT use.

  • Odds ratios adjusted for age, county, year of diagnosis/reference date, number of full-term pregnancies, and duration of hormonal contraception.